(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 49.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.14%.
Autolus Therapeutics's revenue in 2026 is $92,624,000.On average, 12 Wall Street analysts forecast AUTL's revenue for 2026 to be $35,031,424,553, with the lowest AUTL revenue forecast at $31,744,400,596, and the highest AUTL revenue forecast at $41,081,145,569. On average, 12 Wall Street analysts forecast AUTL's revenue for 2027 to be $55,214,017,806, with the lowest AUTL revenue forecast at $39,124,900,542, and the highest AUTL revenue forecast at $72,729,730,082.
In 2028, AUTL is forecast to generate $84,975,557,796 in revenue, with the lowest revenue forecast at $52,919,754,930 and the highest revenue forecast at $114,300,602,298.